In this study, participants with TRD were randomly assigned to receive intranasal Spravato monotherapy at either 56mg or 84mg, administered twice weekly, or placebo nasal spray for 4 weeks.

Johnson & Johnson has priced its new Spravato nasal spray for treatment-resistant depression (TRD) too high to offer value for money, says a US cost-effectiveness body. The Institute for Clinical ...

The Food and Drug Administration (FDA) has expanded its approval of a ketamine nasal spray, Spravato (esketamine), as a standalone therapy for adults with treatment-resistant depression.

It's called Spravato, made by Johnson and Johnson and it works faster than standard oral antidepressants. Spravato was first approved back in 2019, but at that time, patients had to use it with an ...

At least 21 million adults in the U.S. have experienced depression. And, while oral antidepressant medications are a common treatment, they don't work for everyone. Now, the Food and Drug ...

Living Local 15 host Jessica Williams is joined by Sean Goddard, a Psychiatric Nurse Practitioner and Owner of Viking Psychiatry, to speak about the recent approval for Spravato as a monotherapy ...

Parkside Psychiatric Hospital in Tulsa has an on-site Spravato outpatient clinic that sees over 20 patients per week. According to Parkside, these patients are seen at least twice a week for the ...

Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the immediate impact Spravato has had on patients with treatment-resistant ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of MDD in those who have not responded to at least two oral antidepressants. Hundreds of ...

Spravato is the brand name for an esketamine nasal spray that the FDA has approved for treatment-resistant depression. A doctor may prescribe the drug for depression that has not responded to ...